Cargando…

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

BACKGROUND: Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer’s disease (AD). METHODS: In this rando...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ostrowitzki, Susanne, Lasser, Robert A., Dorflinger, Ernest, Scheltens, Philip, Barkhof, Frederik, Nikolcheva, Tania, Ashford, Elizabeth, Retout, Sylvie, Hofmann, Carsten, Delmar, Paul, Klein, Gregory, Andjelkovic, Mirjana, Dubois, Bruno, Boada, Mercè, Blennow, Kaj, Santarelli, Luca, Fontoura, Paulo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723032/ https://www.ncbi.nlm.nih.gov/pubmed/29221491 http://dx.doi.org/10.1186/s13195-017-0318-y

Ejemplares similares

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2018)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
por: Klein, Gregory, et al.
Publicado: (2019)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease
por: Retout, Sylvie, et al.
Publicado: (2022)

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
por: Nave, Stephane, et al.
Publicado: (2017)

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
por: Aldea, Roxana, et al.
Publicado: (2022)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease
por: Novakovic, Dijana, et al.
Publicado: (2013)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Prodromal frontotemporal dementia: clinical features and predictors of progression
por: Benussi, Alberto, et al.
Publicado: (2021)

36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
por: Soininen, Hilkka, et al.
Publicado: (2020)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Immune signatures of prodromal multiple sclerosis in monozygotic twins
por: Gerdes, Lisa Ann, et al.
Publicado: (2020)

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
por: Soininen, Hilkka, et al.
Publicado: (2017)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
por: Parbo, Peter, et al.
Publicado: (2020)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Time Perception in Prodromal Alzheimer's Dementia and in Prodromal Dementia With Lewy Bodies
por: Pai, Ming-Chyi, et al.
Publicado: (2021)

FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD
por: Kantarci, Kejal, et al.
Publicado: (2021)

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design
por: Bertens, Daniela, et al.
Publicado: (2017)

Long-Term Retention Deficit Involvement in Prodromal Alzheimer’s Disease
por: Jonin, P. Y., et al.
Publicado: (2010)

Understanding the schizophrenia prodrome
por: George, Manju, et al.
Publicado: (2017)

The prodromes of Parkinson's disease
por: Rees, Richard Nathaniel, et al.
Publicado: (2018)

Oscillatory Activity of the Hippocampus in Prodromal Alzheimer’s Disease: A Source-Space Magnetoencephalography Study
por: Luppi, Janne J., et al.
Publicado: (2022)

The schizophrenia prodrome: promise for prevention
por: Cornblatt, Barbara
Publicado: (2001)

The Concept of Prodromal Parkinson’s Disease
por: Mahlknecht, Philipp, et al.
Publicado: (2015)

Editorial: Prodromal Parkinson's Disease
por: Crosiers, David, et al.
Publicado: (2021)

Complementary pre‐screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
por: Boada, Mercè, et al.
Publicado: (2021)

Prodromal Dementia with Lewy Bodies: A Case Series of the 3 Prodromal Types from Clinical Practice
por: Tholanikunnel, Tracy, et al.
Publicado: (2023)

Inflammaging as a prodrome to Alzheimer's disease
por: Giunta, Brian, et al.
Publicado: (2008)

Amyloid imaging in prodromal Alzheimer's disease
por: Ossenkoppele, Rik, et al.
Publicado: (2011)

Genealogy of Instruments for Prodrome Evaluation of Psychosis
por: Daneault, Jean-Gabriel, et al.
Publicado: (2013)

Is pharmacological intervention necessary in prodromal schizophrenia?
por: Zhao, Jingping, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_t8b189dc0733b3iah41pno2505